STRIkER
Phase NA Withdrawn
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
Phase 1/2 Withdrawn
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Phase 1/2 Withdrawn
Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
Phase 1 Withdrawn
FOODPANC
Phase NA Withdrawn
BESTa
Phase NA Withdrawn
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Phase 2 Withdrawn
Living Donor Liver Transplantation for CRC Liver Metastases
Phase NA Withdrawn
Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)
Withdrawn
Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis
Phase NA Withdrawn
Does Genetic Susceptibility for Bleeding Affect Quantitative Faecal Immunochemical Test (qFIT) Results?
Withdrawn
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Phase 2 Withdrawn
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
Phase 1 Withdrawn
PRISM
Phase 2 Withdrawn
Imaging of the Esophagus Using a SECM Capsule
Phase NA Withdrawn
A Percutaneous Ultrasound Device With Needle Guide for Vascular Access
Phase NA Withdrawn
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
Phase 1/2 Withdrawn
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Phase 1 Withdrawn
EMPIRE
Phase 2 Withdrawn
Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2)
Phase NA Withdrawn
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
Phase NA Withdrawn
Dyadic Text-Messaging Micro-Intervention
Phase NA Withdrawn
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Phase 1 Withdrawn
PRIMUS006
Phase 2 Withdrawn
DIGELECTROSTIM
Phase NA Withdrawn
TCR1020-CD8 T Cells in KRAS-mutated Cancers
Phase 1 Withdrawn
TRACT DNA
Withdrawn
A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer
Withdrawn
Defining Musical Toxicity and Its Effect on Patient Well-being
Withdrawn
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
Withdrawn
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Phase 2 Withdrawn
Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-
Phase 2 Withdrawn
Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
Phase 2 Withdrawn
Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy
Withdrawn
CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Phase 2 Withdrawn
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
Phase 2 Withdrawn
ProPeC
Phase 2 Withdrawn
CSIEMR
Phase NA Withdrawn
C-LST
Phase NA Withdrawn
BERST
Phase 4 Withdrawn
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
Phase NA Withdrawn
HepQuant
Phase NA Withdrawn
UNTIRE: Cancer-related Fatigue With Digital Treatment
Phase NA Withdrawn
XACT-PANC-2
Phase 2 Withdrawn
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Phase 2 Withdrawn
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
Phase 1 Withdrawn
Molecular Effects of Aspirin & Metformin on Colonic Epithelium
Phase NA Withdrawn
MAGnET
Withdrawn
Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies
Phase 4 Withdrawn
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
Phase 2 Withdrawn